-
Je něco špatně v tomto záznamu ?
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023
K. Peris, MC. Fargnoli, R. Kaufmann, P. Arenberger, L. Bastholt, NB. Seguin, V. Bataille, L. Brochez, V. Del Marmol, R. Dummer, AM. Forsea, C. Gaudy-Marqueste, CA. Harwood, A. Hauschild, C. Höller, L. Kandolf, NWJ. Kellerners-Smeets, A. Lallas,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
- MeSH
- bazocelulární karcinom * diagnóza terapie MeSH
- imunoterapie MeSH
- konsensus MeSH
- lidé MeSH
- nádory kůže * diagnóza terapie MeSH
- proteiny hedgehog MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from European Association of Dermato-Oncology (EADO), European Dermatology Forum, European Society for Radiotherapy and Oncology (ESTRO), Union Européenne des Médecins Spécialistes, and the European Academy of Dermatology and Venereology developed updated recommendations on diagnosis and treatment of BCC. BCCs were categorised into 'easy-to-treat' (common) and 'difficult-to-treat' according to the new EADO clinical classification. Diagnosis is based on clinico-dermatoscopic features, although histopathological confirmation is mandatory in equivocal lesions. The first-line treatment of BCC is complete surgery. Micrographically controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites. Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial and low-risk nodular BCCs. Management of 'difficult-to-treat' BCCs should be discussed by a multidisciplinary tumour board. Hedgehog inhibitors (HHIs), vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCC. Immunotherapy with anti-PD1 antibodies (cemiplimab) is a second-line treatment in patients with a progression of disease, contraindication, or intolerance to HHI therapy. Radiotherapy represents a valid alternative in patients who are not candidates for or decline surgery, especially elderly patients. Electrochemotherapy may be offered when surgery or radiotherapy is contraindicated. In Gorlin patients, regular skin examinations are required to diagnose and treat BCCs at an early stage. Long-term follow-up is recommended in patients with high-risk BCC, multiple BCCs, and Gorlin syndrome.
1st Department of Dermatology Aristotle University Thessaloniki Greece
Aix Marseille University Dermatology and Skin Cancer Department APHM Marseille France
Centre for Dermatooncology Department of Dermatology Eberhard Karls University Tuebingen Germany
Coimbra Hospital and Universitary Centre Coimbra Portugal
Department of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila Italy
Department of Dermatology and Venereology University Hospital Center Zagreb Croatia
Department of Dermatology Erasme Hospital Université Libre de Bruxelles Brussels Belgium
Department of Dermatology Faculty of Medicine Military Medical Academy Belgrade Serbia
Department of Dermatology Instituto Valenciano de Oncologia Valencia Spain
Department of Dermatology Maastricht University Medical Centre Maastricht Netherlands
Department of Dermatology Medical University of Vienna Austria
Department of Dermatology Skin Cancer Center Ruhr University Bochum 44791 Bochum Germany
Department of Dermatology University Hospital Ghent Ghent Belgium
Department of Dermatology University Hospital Zurich and University Zurich Switzerland
Department of Dermatology University of Kiel Kiel Germany
Department of Dermatology Venereology and Allergology University Hospital Frankfurt Germany
Department of Dermatovenereology 3rd Faculty of Medicine Charles University Prague Czech Republic
Department of Oncology Odense University Hospital Denmark
Dermatology Clinic University of Trieste Trieste Italy
Dermatology Department Saint Louis Hospital Paris France
Dermatology Medicine School University of Seville University Hospital Virgen Macarena Seville Spain
Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy
GROW School for Oncology and Reproduction Maastricht University Maastricht Netherlands
Institute of Dermatology Catholic University of the Sacred Heart Rome Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016103
- 003
- CZ-PrNML
- 005
- 20231026110428.0
- 007
- ta
- 008
- 231013s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2023.113254 $2 doi
- 035 __
- $a (PubMed)37604067
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Peris, Ketty $u Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. Electronic address: ketty.peris@unicatt.it
- 245 10
- $a European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023 / $c K. Peris, MC. Fargnoli, R. Kaufmann, P. Arenberger, L. Bastholt, NB. Seguin, V. Bataille, L. Brochez, V. Del Marmol, R. Dummer, AM. Forsea, C. Gaudy-Marqueste, CA. Harwood, A. Hauschild, C. Höller, L. Kandolf, NWJ. Kellerners-Smeets, A. Lallas, U. Leiter, J. Malvehy, B. Marinović, Z. Mijuskovic, D. Moreno-Ramirez, E. Nagore, P. Nathan, AJ. Stratigos, E. Stockfleth, L. Tagliaferri, M. Trakatelli, R. Vieira, I. Zalaudek, C. Garbe, EADO”A, EDF”B, ESTRO”C, UEMS”D and EADV”E
- 520 9_
- $a Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from European Association of Dermato-Oncology (EADO), European Dermatology Forum, European Society for Radiotherapy and Oncology (ESTRO), Union Européenne des Médecins Spécialistes, and the European Academy of Dermatology and Venereology developed updated recommendations on diagnosis and treatment of BCC. BCCs were categorised into 'easy-to-treat' (common) and 'difficult-to-treat' according to the new EADO clinical classification. Diagnosis is based on clinico-dermatoscopic features, although histopathological confirmation is mandatory in equivocal lesions. The first-line treatment of BCC is complete surgery. Micrographically controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites. Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial and low-risk nodular BCCs. Management of 'difficult-to-treat' BCCs should be discussed by a multidisciplinary tumour board. Hedgehog inhibitors (HHIs), vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCC. Immunotherapy with anti-PD1 antibodies (cemiplimab) is a second-line treatment in patients with a progression of disease, contraindication, or intolerance to HHI therapy. Radiotherapy represents a valid alternative in patients who are not candidates for or decline surgery, especially elderly patients. Electrochemotherapy may be offered when surgery or radiotherapy is contraindicated. In Gorlin patients, regular skin examinations are required to diagnose and treat BCCs at an early stage. Long-term follow-up is recommended in patients with high-risk BCC, multiple BCCs, and Gorlin syndrome.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a proteiny hedgehog $7 D053823
- 650 _2
- $a konsensus $7 D032921
- 650 12
- $a bazocelulární karcinom $x diagnóza $x terapie $7 D002280
- 650 _2
- $a imunoterapie $7 D007167
- 650 12
- $a nádory kůže $x diagnóza $x terapie $7 D012878
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Fargnoli, Maria Concetta $u Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
- 700 1_
- $a Kaufmann, Roland $u Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Germany
- 700 1_
- $a Arenberger, Petr $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Bastholt, Lars $u Department of Oncology, Odense University Hospital, Denmark
- 700 1_
- $a Seguin, Nicole Basset $u Dermatology Department, Saint-Louis Hospital, Paris, France
- 700 1_
- $a Bataille, Veronique $u Twin Research and Genetic Epidemiology Unit, School of Basic & Medical Biosciences, King's College London, London SE1 7EH, UK
- 700 1_
- $a Brochez, Lieve $u Department of Dermatology, University Hospital Ghent, Ghent, Belgium
- 700 1_
- $a Del Marmol, Veronique $u Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
- 700 1_
- $a Dummer, Reinhard $u Department of Dermatology, University Hospital Zurich and University Zurich, Switzerland
- 700 1_
- $a Forsea, Ana-Marie $u Department of Oncologic Dermatology, Elias University Hospital Bucharest, Carol Davila University of Medicine and Pharmacy Bucharest, Bucharest, Romania
- 700 1_
- $a Gaudy-Marqueste, Caroline $u Aix-Marseille University, Dermatology and Skin Cancer Department, APHM, Marseille, France
- 700 1_
- $a Harwood, Catherine A $u Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- 700 1_
- $a Hauschild, Axel $u Department of Dermatology, University of Kiel, Kiel, Germany
- 700 1_
- $a Höller, Christoph $u Department of Dermatology, Medical University of Vienna, Austria
- 700 1_
- $a Kandolf, Lidija $u Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia
- 700 1_
- $a Kellerners-Smeets, Nicole W J $u GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, Netherlands; Department of Dermatology, Maastricht University Medical Centre, Maastricht, Netherlands
- 700 1_
- $a Lallas, Aimilios $u First Department of Dermatology, Aristotle University, Thessaloniki, Greece
- 700 1_
- $a Leiter, Ulrike $u Centre for Dermatooncology, Department of Dermatology, Eberhard-Karls University, Tuebingen, Germany
- 700 1_
- $a Malvehy, Josep $u Department of Dermatology, Hospital Clínic de Barcelona (Melanoma Unit), University of Barcelona, IDIBAPS, Barcelona & CIBERER, Barcelona, Spain
- 700 1_
- $a Marinović, Branka $u Department of Dermatology and Venereology, University Hospital Center Zagreb, Croatia
- 700 1_
- $a Mijuskovic, Zeljko $u Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia
- 700 1_
- $a Moreno-Ramirez, David $u Dermatology. Medicine School, University of Seville, University Hospital Virgen Macarena, Seville-Spain
- 700 1_
- $a Nagore, Eduardo $u Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain
- 700 1_
- $a Nathan, Paul $u Mount-Vernon Cancer Centre, Northwood, UK
- 700 1_
- $a Stratigos, Alexander J $u First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece
- 700 1_
- $a Stockfleth, Eggert $u Department of Dermatology, Skin Cancer Center, Ruhr-University Bochum, 44791 Bochum, Germany
- 700 1_
- $a Tagliaferri, Luca $u Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Rome, Italy
- 700 1_
- $a Trakatelli, Myrto $u Second Department of Dermatology, Aristotle University Medical School, Papageorgiou General Hospital, Thessaloniki, Greece
- 700 1_
- $a Vieira, Ricardo $u Coimbra Hospital and Universitary Centre, Coimbra, Portugal
- 700 1_
- $a Zalaudek, Iris $u Dermatology Clinic, University of Trieste, Trieste, Italy
- 700 1_
- $a Garbe, Claus $u Centre for Dermatooncology, Department of Dermatology, Eberhard-Karls University, Tuebingen, Germany
- 710 2_
- $a EADO”A, EDF”B, ESTRO”C, UEMS”D and EADV”E
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 192, č. - (2023), s. 113254
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37604067 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026110421 $b ABA008
- 999 __
- $a ok $b bmc $g 1999928 $s 1202465
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 192 $c - $d 113254 $e 20230728 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20231013
